Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies

Sharon B Wigal,1 Tim Wigal,1 Mary Hobart,2 Jessica J Madera,3 Ross A Baker,3 Eva Kohegyi,3 Anthony McKinney,4 Timothy E Wilens5 1AVIDA Inc., Newport Beach, California, USA; 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA; 3Otsuka Pharmaceutical Developm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	adhd rating scale-iv efficacy norepinephrine-dopamine-serotonin reuptake inhibitor tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3e6cabdeeaf74eb7b39e551e80cb4f1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e6cabdeeaf74eb7b39e551e80cb4f1e
record_format	dspace
spelling	oai:doaj.org-article:3e6cabdeeaf74eb7b39e551e80cb4f1e2021-12-02T15:21:59ZSafety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies1178-2021https://doaj.org/article/3e6cabdeeaf74eb7b39e551e80cb4f1e2020-06-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-centanafadine-sustained-release-in-adults-with--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Sharon B Wigal,1 Tim Wigal,1 Mary Hobart,2 Jessica J Madera,3 Ross A Baker,3 Eva Kohegyi,3 Anthony McKinney,4 Timothy E Wilens5 1AVIDA Inc., Newport Beach, California, USA; 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA; 3Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey, USA; 4Ethismos Research, Inc, Cambridge, Massachusetts, USA; 5Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USACorrespondence: Timothy E WilensDivision of Child and Adolescent Psychiatry, Center for Addiction Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USATel +1 617-643-3481Fax +1 617-724-3742Email twilens@mgh.harvard.eduPurpose: Two phase 2 studies evaluated the efficacy and tolerability of centanafadine sustained-release (SR) for adults with attention-deficit/hyperactivity disorder (ADHD).Patients and Methods: In a phase 2a, flexible-dose, single-blind study, 41 male patients (aged 18‒55 years) with a diagnosis of ADHD (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) were titrated with centanafadine-SR 200‒300, 400, or 500 mg/d for 2 weeks, and then were treated with the titrated dose for 2 weeks. In a phase 2b, randomized, double-blind, placebo-controlled, crossover study, 85 male and female patients (aged 18‒60 years) with a diagnosis of ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) were titrated to target doses of centanafadine-SR 400, 500, 600, or 800 mg/d over the course of 1 week, and then received their titrated dose for 3 weeks. The primary outcome in both studies was mean total ADHD Rating Scale-IV (ADHD-RS-IV) score.Results: In the phase 2a study, mean ADHD-RS-IV total score decreased by 21.41 (standard deviation 10.74) from the start of active centanafadine-SR treatment to the end of week 4 (P< 0.001). In the phase 2b study, centanafadine-SR treatment resulted in a statistically significant improvement in ADHD-RS-IV from baseline to week 3 compared with placebo (least-squares mean − 16.5 vs − 8.4; P< 0.001; effect size 0.66), with significant efficacy demonstrated as early as week 1. Centanafadine-SR was generally well tolerated at doses ≤ 400 mg. Most treatment-emergent adverse events (TEAEs) were mild or moderate; decreased appetite, headache, and nausea were the most frequently reported. In the 2 studies, 13 of 120 patients discontinued centanafadine-SR due to TEAEs; however, only 1 patient who received ≤ 400 mg discontinued due to a TEAE. No serious TEAEs were reported at any dose.Conclusion: These results support the continued development of centanafadine-SR at doses up to 400 mg/d.Keywords: ADHD Rating Scale-IV, efficacy, norepinephrine-dopamine-serotonin reuptake inhibitor, tolerabilityWigal SBWigal THobart MMadera JJBaker RAKohegyi EMcKinney AWilens TEDove Medical Pressarticleadhd rating scale-ivefficacynorepinephrine-dopamine-serotonin reuptake inhibitortolerabilityNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 1411-1426 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	adhd rating scale-iv efficacy norepinephrine-dopamine-serotonin reuptake inhibitor tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	adhd rating scale-iv efficacy norepinephrine-dopamine-serotonin reuptake inhibitor tolerability Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wigal SB Wigal T Hobart M Madera JJ Baker RA Kohegyi E McKinney A Wilens TE Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
description	Sharon B Wigal,1 Tim Wigal,1 Mary Hobart,2 Jessica J Madera,3 Ross A Baker,3 Eva Kohegyi,3 Anthony McKinney,4 Timothy E Wilens5 1AVIDA Inc., Newport Beach, California, USA; 2Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA; 3Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey, USA; 4Ethismos Research, Inc, Cambridge, Massachusetts, USA; 5Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USACorrespondence: Timothy E WilensDivision of Child and Adolescent Psychiatry, Center for Addiction Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USATel +1 617-643-3481Fax +1 617-724-3742Email twilens@mgh.harvard.eduPurpose: Two phase 2 studies evaluated the efficacy and tolerability of centanafadine sustained-release (SR) for adults with attention-deficit/hyperactivity disorder (ADHD).Patients and Methods: In a phase 2a, flexible-dose, single-blind study, 41 male patients (aged 18‒55 years) with a diagnosis of ADHD (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) were titrated with centanafadine-SR 200‒300, 400, or 500 mg/d for 2 weeks, and then were treated with the titrated dose for 2 weeks. In a phase 2b, randomized, double-blind, placebo-controlled, crossover study, 85 male and female patients (aged 18‒60 years) with a diagnosis of ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) were titrated to target doses of centanafadine-SR 400, 500, 600, or 800 mg/d over the course of 1 week, and then received their titrated dose for 3 weeks. The primary outcome in both studies was mean total ADHD Rating Scale-IV (ADHD-RS-IV) score.Results: In the phase 2a study, mean ADHD-RS-IV total score decreased by 21.41 (standard deviation 10.74) from the start of active centanafadine-SR treatment to the end of week 4 (P< 0.001). In the phase 2b study, centanafadine-SR treatment resulted in a statistically significant improvement in ADHD-RS-IV from baseline to week 3 compared with placebo (least-squares mean − 16.5 vs − 8.4; P< 0.001; effect size 0.66), with significant efficacy demonstrated as early as week 1. Centanafadine-SR was generally well tolerated at doses ≤ 400 mg. Most treatment-emergent adverse events (TEAEs) were mild or moderate; decreased appetite, headache, and nausea were the most frequently reported. In the 2 studies, 13 of 120 patients discontinued centanafadine-SR due to TEAEs; however, only 1 patient who received ≤ 400 mg discontinued due to a TEAE. No serious TEAEs were reported at any dose.Conclusion: These results support the continued development of centanafadine-SR at doses up to 400 mg/d.Keywords: ADHD Rating Scale-IV, efficacy, norepinephrine-dopamine-serotonin reuptake inhibitor, tolerability
format	article
author	Wigal SB Wigal T Hobart M Madera JJ Baker RA Kohegyi E McKinney A Wilens TE
author_facet	Wigal SB Wigal T Hobart M Madera JJ Baker RA Kohegyi E McKinney A Wilens TE
author_sort	Wigal SB
title	Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
title_short	Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
title_full	Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
title_fullStr	Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
title_full_unstemmed	Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
title_sort	safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/3e6cabdeeaf74eb7b39e551e80cb4f1e
work_keys_str_mv	AT wigalsb safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT wigalt safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT hobartm safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT maderajj safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT bakerra safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT kohegyie safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT mckinneya safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies AT wilenste safetyandefficacyofcentanafadinesustainedreleaseinadultswithattentiondeficithyperactivitydisorderresultsofphase2studies
_version_	1718387412928823296

Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies

Ejemplares similares